Ocular Phenotype and Complications in Patients with Tuberous Sclerosis Complex (TSC)

被引:0
|
作者
Zweipfenning, Florian [1 ]
Toelle, Sandra P. [2 ]
Gerth-Kahlert, Christina [1 ]
机构
[1] Univ Spital Zurich, Augenklin, Frauenklin Str 24, CH-8091 Zurich, Switzerland
[2] Univ Kinderspital Zurich, Abt Neuropadiatrie, Zurich, Switzerland
关键词
tuberous sclerosis complex; inverse optic atrophy; vigabatrin toxicity; RETINAL ASTROCYTOMAS; VIGABATRIN TOXICITY; RECOMMENDATIONS;
D O I
10.1055/a-0804-1816
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background Evaluation and comparison of the ocular phenotype in patients diagnosed with tuberous sclerosis complex (TSC). Analysis of ocular complications during follow-up. Patients and Methods A retrospective chart review was performed of patients with TSC who had received an ocular examination at the eye clinic of the University Hospital Zurich. Data were analysed on visual acuity (VA) assessment, refraction, anterior and posterior eye examination including the distinction of different types of hamartomas and, when available, visual fields. The study was approved by the Cantonal Ethics Committee of Zurich. Results A total of 30 patients who were diagnosed with TSC (19 female, 11 male) were included in the analysis. The age at first examination varied from 7 months to 44 years (mean 13.3 years, standard deviation 11.31). 17/30 patients received a follow-up examination between 4 months and 19 years (mean 4.3 years, standard deviation 5.24). Data of VA were available in 26/30 patients, of whom 22 had normal vision in both eyes. The causes of reduced VA in the 4 patients were: complications of a subependymal giant cell astrocytoma followed by a bilateral optic nerve atrophy; vigabatrin-associated optic atrophy; anterior segment dysgenesis; unilateral amblyopia. Adequate VA testing was not possible in 4 patients because of intellectual disabilities. Retinal hamartomas were described in 15/30 patients: 8 unilateral, 7 bilateral. The flat hamartoma type was described in 10/15 patients, the multinodular type in 6/15 patients. Conclusions The ocular phenotype in our patient cohort shows similar TSC involvement to that described in the literature. Patients diagnosed with TSC require regular ophthalmic examinations to diagnose secondary ocular complications, such as papilloedema, severe vision loss or visual field constriction.
引用
收藏
页码:462 / 468
页数:7
相关论文
共 50 条
  • [31] Characterisation of TSC1 promoter deletions in tuberous sclerosis complex patients
    Ans M W van den Ouweland
    Peter Elfferich
    Bernard A Zonnenberg
    Willem F Arts
    Tjitske Kleefstra
    Mark D Nellist
    Jose M Millan
    Caroline Withagen-Hermans
    Anneke J A Maat-Kievit
    Dicky J J Halley
    European Journal of Human Genetics, 2011, 19 : 157 - 163
  • [32] Mutation landscape of TSC1/TSC2 in Chinese patients with tuberous sclerosis complex
    Yuhuan Meng
    Changshun Yu
    Meijun Chen
    Xiaokang Yu
    Mingming Sun
    Hui Yan
    Weiwei Zhao
    Shihui Yu
    Journal of Human Genetics, 2021, 66 : 227 - 236
  • [33] Characterisation of TSC1 promoter deletions in tuberous sclerosis complex patients
    van den Ouweland, Ans M. W.
    Elfferich, Peter
    Zonnenberg, Bernard A.
    Arts, Willem F.
    Kleefstra, Tjitske
    Nellist, Mark D.
    Millan, Jose M.
    Withagen-Hermans, Caroline
    Maat-Kievit, Anneke J. A.
    Halley, Dicky J. J.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2011, 19 (02) : 157 - 163
  • [34] Mutational analysis of TSC1 and TSC2 in Danish patients with tuberous sclerosis complex
    Thomas Rosengren
    Santoesha Nanhoe
    Luis Gustavo Dufner de Almeida
    Bitten Schönewolf-Greulich
    Lasse Jonsgaard Larsen
    Caroline Amalie Brunbjerg Hey
    Morten Dunø
    Jakob Ek
    Lotte Risom
    Mark Nellist
    Lisbeth Birk Møller
    Scientific Reports, 10
  • [35] Catastrophic Events Related to Tuberous Sclerosis Complex (TSC) Are Unlikely In a Heterogeneous Adult Cohort of TSC Patients
    Neal, Lauren
    McCain, Sarah
    Boggs, Jane
    Stem, Theodore
    Miles, Matthew
    Strowd, Roy
    NEUROLOGY, 2021, 96 (15)
  • [36] Mutational analysis of TSC1 and TSC2 in Korean patients with tuberous sclerosis complex
    Choi, Ji-Eun
    Chae, Jong-Hee
    Hwang, Yong-Seung
    Kim, Ki-Joong
    BRAIN & DEVELOPMENT, 2006, 28 (07): : 440 - 446
  • [37] Deep phenotyping of patients with Tuberous Sclerosis Complex and no mutation identified in TSC1 and TSC2
    Peron, Angela
    Vignoli, Aglaia
    La Briola, Francesca
    Morenghi, Emanuela
    Tansini, Lucia
    Alfano, Rosa Maria
    Bulfamante, Gaetano
    Terraneo, Silvia
    Ghelma, Filippo
    Banderali, Giuseppe
    Viskochil, David H.
    Carey, John C.
    Canevini, Maria Paola
    EUROPEAN JOURNAL OF MEDICAL GENETICS, 2018, 61 (07) : 403 - 410
  • [38] The tuberous sclerosis complex (TSC) pathway and mechanism of size control
    Potter, CJ
    Pedraza, LG
    Huang, H
    Xu, T
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2003, 31 : 584 - 586
  • [39] Mutational analysis of TSC1 and TSC2 genes in Japanese patients with tuberous sclerosis complex
    Zhang, H
    Nanba, E
    Yamamoto, T
    Ninomiya, H
    Ohno, K
    Mizuguchi, M
    Takeshita, K
    JOURNAL OF HUMAN GENETICS, 1999, 44 (06) : 391 - 396
  • [40] Novel TSC1 and TSC2 gene mutations in Chinese patients with tuberous sclerosis complex
    Yu, Tingting
    He, Yingzhong
    Li, Niu
    Zhou, Yunqing
    Wang, Zhiping
    Fu, Qihua
    Wang, Jiwen
    Wang, Jian
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2017, 154 : 104 - 108